US20030022845A1 - Compositions comprising a mixture of bioflavonols - Google Patents

Compositions comprising a mixture of bioflavonols Download PDF

Info

Publication number
US20030022845A1
US20030022845A1 US10254515 US25451502A US2003022845A1 US 20030022845 A1 US20030022845 A1 US 20030022845A1 US 10254515 US10254515 US 10254515 US 25451502 A US25451502 A US 25451502A US 2003022845 A1 US2003022845 A1 US 2003022845A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
quercetin
composition according
rutin
isoquercetin
bioflavonols
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10254515
Inventor
Herwig Buchholz
Jerzy Meduski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A23B - A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof

Abstract

The present invention relates to novel compositions containing a mixture of two or three bioflavonols like isoquercetin, quercetin-4′-glycoside, rutin and quercetin, which show differences in their pharmacokinetics. These compositions are useful as food supplements possessing preventive properties against damage to human tissues due to their antioxidant properties. Furthermore, these compositions secure a continuum of the presence of bioflavonols having the same aglycone in human plasma over an extended period of time.

Description

  • The present invention relates to novel compositions containing a mixture of two or three bioflavonols like isoquercetin, quercetin-4′-glycoside, rutin and quercetin, which show differences in their pharmacokinetics. These compositions are useful as food supplements possessing preventive properties against damage to human tissues due to their antioxidant properties. Furthermore, these compositions secure a continuum of the presence of bioflavonols in human plasma. [0001]
  • Structures of body tissues are susceptible to damage caused by the oxidative stress, e.g., by the accumulation of reactive oxygen species during ageing, chronic environmental stress, inflammations or general metabolic dysfunctions. The role of reactive oxygen species in aetiology of human diseases (e.g. cancer, atherosclerosis, rheumatoid arthritis, inflammatory bowel diseases, immune system dysfunctions, brain function decline, connective tissue dysfunctions) is well established. Chronic exposure to reactive oxygen species leads to chronic intracellular damage, to oxidative stress and premature ageing. Cells of the human body possess metabolic antioxidant defences which are supported by dietary antioxidants. The early observations of the antioxidant defence metabolic processes involved flavonoids. [0002]
  • Quercetin, an aglycone, isoquercetin, a quercetin glycoside, and rutin, a quercetin rutinoside, are flavonols that are being recently extensively studied due to their antioxidant properties. Gycosylation of an aglycone makes the molecule less reactive towards free radicals and more water-soluble. Kind and the position of the glycosylation are the sources of the pharmacokinetic differences among flavonols that have the same aglycone. [0003]
  • Common glycosylation positions are: the 7-hydroxyl in flavones, isoflavones and dihydroflavones; the 3- and 7-hydroxyl in flavonols and dihydroflavonols; and the 3- and 5-hydroxyl in anthocyanidins. The sugar most usually involved in the glycoside formation is glucose, although galactose, rhamnose, xylose and arabinose also occur, as well as several disaccharides. For example, onions contain mostly isoquercetin, apples contain various quercetin glycosides, galactosides, arabinosides, rhamnosides, xylosides and glucosides. Many plants contain the quercetin disaccharide, rutin. [0004]
  • Flavonols are metabolized by animal cells, especially those of the liver. [0005]
  • No residuals of flavonols are accumulated in the body (see Havsteen B. (1983), Flavonoids, a class of natural products of high pharmacological potency, Biochemical Pharmacology 32(7), 1141-1148). [0006]
  • Also absorption kinetics of flavonols is highly dependent on their chemical structure. The bioavailabilities of isoquercetin, rutin and quercetin differ. The bioavailability of rutin is only 30% of the bioavailability of isoquercetin. Hollman (see Hollman, P. C. H., et al. (1997) Bioavailability of the dietary antioxidant flavonol quercetin in man, Cancer Lett. 114: 139140) explains the superior absorption of isoquercetin by the fact that isoquercetin is actively absorbed using sodium-glucose absorption mechanism. Quercetin is absorbed as an aglycone and is present in the human plasma in its free form (see Noteborn, H. P. J. M. et al. (1997) Oral absorption and metabolism of quercetin and sugar-conjugated derivatives in specific transport systems, Cancer Lett. 114:175-177; Conquer, J. A., et al. (1998) Supplementation with Quercetin Markedly Increases Plasma Quercetin Concentration without Effect on Selected Risk Factors for Heart Disease in Healthy Subjects, J. Nutr. March 1; 128(3): 593-597) and in the glycosylated forms when absorbed as a glycoside. It has been shown that quercetin is preferentially absorbed as its monoglucosides (see Papanga, G. Rice-Evans, C. A. (1997) The identification of flavonoids as glycosides in human plasma, FEBS Lett. 401(1): 78-82; and [0007]
  • Hollman, P. C. H. et al. (1997) Relative bioavailability of the antioxidant flavonoid quercetin from various foods in man, FEBS Lett., November 24; 418(1-2): 152-156). [0008]
  • As expected all of these compounds, quercetin, isoquercetin, quercetin4′-glycoside and rutin differ in their pharmacokinetics. [0009]
  • For orally administered isoquercetin the time to reach peak is about 0.70 h (see Hollman, P. C. H., (1997) Determinants of the absorption of the dietary flavonoid quercetin in man; Proefschrift). For the free quercetin the time to peak could be evaluated at about 3 h (see Da Silva, E. L., et al. (1998) Inhibition of mammalian 15-lipoxygenase-dependent lipid peroxidation in low-density lipoprotein by quercetin and quercetin monoglucosides, Archives of Biochemistry and Biophysics 349, (2) January 15, 313-320). For rutin the time was about 7 to 9 h (see Holiman). [0010]
  • After having reached the peak (after different periods of time), the concentration of the flavonols quickly decreases by metabolization. [0011]
  • Therefore, it is not possible so far to obtain a continuum presence of bioflavonols in the human plasma for an extended time span. [0012]
  • However, it would be desirable to have orally applicable formulation of these specific antioxidants leading to an increased and continued present concentration of bioflavonols having the same aglycone in the human plasma over a prolonged period of time. [0013]
  • Accordingly, there was a need for a composition useful for the enhancement of antioxidant activity in human plasma during an extended time span in order to prevent damage to human tissues. [0014]
  • Now it has been found that the mixture of two or three flavonols, when administered jointly to humans, will secure the very similar concentrations of flavonols in plasma assuring similar pharmacological and nutraceutical activity for an extended time period. [0015]
  • Object of the present invention is therefore an orally applicable composition comprising a mixture of the bioflavonols isoquercetin (quercetin-3-glucoside) or quercetin-4′-glucoside and rutin, optionally together with quercetin. [0016]
  • It has been found that a mixture of isoquercetin or quercetin-4′-glucoside, quercetin and rutin in the molar ratio of 1:1,5:3 or similar ratios will secure pharmacological and nutraceutical activity for an extended period of time up to 48 hours. [0017]
  • The composition of these antioxidants according to the present invention is highly suitable for treatments like cardiovascular disease or the prevention of neoplastic growth. [0018]
  • Besides, the antiviral properties of quercetin are also effective in these compositions. [0019]
  • In a preferred embodiment of the present invention the composition comprises isoquercetin and rutin in a molar ration of about 1:4. When administered to humans, this composition will secure up to 24 hours a continued high concentration of flavonols in plasma assuring similar pharmacological activity during the 24-hour time period. [0020]
  • It has been found that these combinations are most effective in prevention of and in defence against stress dysfunctions, especially against oxidative damage of living tissues. Furthermore, the combinations according to this invention will secure pharmacological and nutraceutical effectiveness for an extended period time for specially designed treatments with these specific antioxidants, e.g. treatment of cardiovascular disease, or the prevention of neoplastic growth. The effect of the continuity of their concentrations is obtained by the summation of their specific concentration kinetics in the human body. [0021]
  • The daily dose of the mixture of the flavonols that have the same aglycone is about 100 mg of quercetin glycoside and 400 mg of rutin. It is possible that the dose may be increased to an expected maximum of about 400 mg of quercetin glycoside and 1600 mg of rutin, maintaining the proportion of flavonols of 1:4 as discussed above. For the mixture of isoquercetin or quercetin-4′-glucoside, quercetin and rutin in the molar ratio of 1:1,5:3 a similar daily dose is suggested like about 100 mg quercetin glycoside, 150 mg of quercetin and 300 mg of rutin up to a maximum dose of about 400 mg of quercetin glycoside, 600 mg of quercetin and 1200 mg of rutin, always maintaining the proportion, [0022]
  • The compositions according to the present invention may be used in form of tablets, capsules or syrups with usable excipients. [0023]
  • The compositions of the present invention preferably are useful as food supplements, but they may also be administered in a pharmaceutical treatment. [0024]
  • The present invention makes available: [0025]
  • a method of maintaining a continued presence of high concentrations of bioflavonols in human plasma for an extended period of time, [0026]
  • a method of protection against oxidative damage to human organs, tissues and cells, [0027]
  • a method of supporting a pharmacological treatment of a disease or dysfunction caused by oxidative damage, [0028]
  • a method of prevention of cardiovascular diseases, and other damage to vascular tissues, of bacterial and viral infections, of metabolic dysfunctions involving oxidative damages or of neoplastic growth, [0029]
  • by oral administration of a composition described above. [0030]
  • The decision which further ingredients should be components of a composition useful in one of the above-mentioned methods depends on the special indication. Usually, if the composition is administered as a way of protection or prevention, useful further ingredients may be vitamins, salts of Mg, Ca, K, Fe and trace elements in known amounts as used in food supplements. Compositions useful in a method of supporting pharmacological treatments may differ from them. [0031]
  • Therefore, a highly efficient dietary antioxidant composition is prepared using among other ingredients the mixtures of isoquercetin or quercetin4′-glycoside and rutin, optionally together with quercetin. The advantageous properties of these compositions are induced by the effect of building a kind of bioflavanoid complex with delayed release of the bioflavonols. [0032]
  • A subject of this invention is that in humans the oral administration of a mixture of isoquercetin or quercetin-4′-glycoside and rutin, optionally together with quercetin, with a suitable molar ratio described above, conveys sufficient protection against oxidative damages, due to a continued presence of bioflavonols assuring similar pharmacological and nutraceutical activity during a prolonged period of time. [0033]
  • The entire disclosure of all applications, patents and publications, cited above and below are hereby incorporated by reference. [0034]
  • From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention and, without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various applications and conditions.[0035]
  • EXAMPLE 1
  • A composition according to this invention is prepared by mixing 400 mg rutin with 100 mg isoquercetin. The results of this formula are shown in diagram 1. [0036]

Claims (12)

1. Orally applicable composition comprising a mixture of the bioflavonols isoquercetin (quercetin-3-glucoside) or quercetin-4′-glucoside and rutin, optionally together with quercetin.
2. Composition according to claim 1 comprising as flavonols isoquercetin and rutin.
3. Composition according to claim 2 comprising isoquercetin and rutin in a molar ratio of about 1:4.
4. Composition according to claim 3 characterised in that it maintains the very similar concentrations of flavonols in plasma up to 24 hours assuring similar pharmacological and nutraceutical activity, when administered to humans.
5. Composition according to claim 1 comprising isoquercetin or quercetin-4′-glycoside, quercetin and rutin.
6. Composition according to claim 5 comprising isoquercetin or quercetin-4′-glycoside, quercetin and rutin in a molar ration of about 1:1,5:3.
7. Composition according to claim 6 characterised in that it maintains the very similar concentrations of flavonols in plasma up to 48 hours assuring similar pharmacological and nutraceutical activity, when administered to humans.
8. Method of maintaining a continued presence of high concentrations of bioflavonols in human plasma for an extended period of time which comprises orally administering a composition according to claim 1.
9. Method of protection against oxidative damage to human organs, tissues and cells which comprises orally administering a composition according to claim 1.
10. Method of supporting a pharmacological treatment of a disease or dysfunction caused by oxidative damage, which comprises orally administering a composition according to claim 1.
11. A method of using the composition according to claim 1 which comprises employing the composition of claim 1 as a food supplement.
12. Pharmaceutical composition containing a pharmaceutically active ingredient, a pharmaceutically acceptable carrier and a composition according to claim 1.
US10254515 1998-10-29 2002-09-26 Compositions comprising a mixture of bioflavonols Abandoned US20030022845A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US10608098 true 1998-10-29 1998-10-29
EP99105035.2 1999-03-22
EP99105035 1999-03-22
US09830118 US6514527B1 (en) 1998-10-29 1999-10-16 Compositions comprising a mixture of bioflavonols
US10254515 US20030022845A1 (en) 1998-10-29 2002-09-26 Compositions comprising a mixture of bioflavonols

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10254515 US20030022845A1 (en) 1998-10-29 2002-09-26 Compositions comprising a mixture of bioflavonols

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP1999/007865 Division WO2000025795A1 (en) 1998-10-29 1999-10-16 Compositions comprising a mixture of bioflavonols
US09830118 Division US6514527B1 (en) 1998-10-29 1999-10-16 Compositions comprising a mixture of bioflavonols

Publications (1)

Publication Number Publication Date
US20030022845A1 true true US20030022845A1 (en) 2003-01-30

Family

ID=26152928

Family Applications (2)

Application Number Title Priority Date Filing Date
US09830118 Expired - Fee Related US6514527B1 (en) 1998-10-29 1999-10-16 Compositions comprising a mixture of bioflavonols
US10254515 Abandoned US20030022845A1 (en) 1998-10-29 2002-09-26 Compositions comprising a mixture of bioflavonols

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09830118 Expired - Fee Related US6514527B1 (en) 1998-10-29 1999-10-16 Compositions comprising a mixture of bioflavonols

Country Status (1)

Country Link
US (2) US6514527B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060111308A1 (en) * 2004-11-16 2006-05-25 Wendye Robbins Methods and compositions for therapeutic treatment
US20070087977A1 (en) * 2004-11-16 2007-04-19 Wendye Robbins Methods and compositions for treating pain

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10240923A1 (en) * 2002-09-02 2004-03-04 Merck Patent Gmbh Flavonoid derivatives for the treatment of eczema
WO2007150063A3 (en) * 2006-06-23 2008-03-13 Cargill Inc Compositions for lowering blood serum cholesterol and use in foods, beverages, and health supplements

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6068846A (en) * 1998-08-05 2000-05-30 Melaleuca, Incorporated Methods and materials for treating depression and mood disorder
US6113907A (en) * 1997-04-15 2000-09-05 University Of Southern California Pharmaceutical grade St. John's Wort

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0724560B2 (en) * 1990-06-01 1995-03-22 株式会社ヤクルト本社 Plant extract-containing beverage
JP3016835B2 (en) 1990-08-19 2000-03-06 三栄源エフ・エフ・アイ株式会社 Browning prevention method of ascorbic acid
JPH06199693A (en) 1992-03-06 1994-07-19 Kunihiko Kato Agent for amelioration and treatment of ischemic disease
JPH06199697A (en) 1992-03-06 1994-07-19 Kunihiko Kato Antiviral, antibacterial and fungicidal agent

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6113907A (en) * 1997-04-15 2000-09-05 University Of Southern California Pharmaceutical grade St. John's Wort
US6068846A (en) * 1998-08-05 2000-05-30 Melaleuca, Incorporated Methods and materials for treating depression and mood disorder

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060111308A1 (en) * 2004-11-16 2006-05-25 Wendye Robbins Methods and compositions for therapeutic treatment
US20070087977A1 (en) * 2004-11-16 2007-04-19 Wendye Robbins Methods and compositions for treating pain
US20090076053A1 (en) * 2004-11-16 2009-03-19 Wendye Robbins Methods and compositions for treating pain
US20090088394A1 (en) * 2004-11-16 2009-04-02 Wendye Robbins Methods and compositions for therapeutic treatment

Also Published As

Publication number Publication date Type
US6514527B1 (en) 2003-02-04 grant

Similar Documents

Publication Publication Date Title
Crozier et al. Bioavailability of dietary flavonoids and phenolic compounds
Schwedhelm et al. Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress
Tiwari Imbalance in antioxidant defence and human diseases: Multiple approach of natural antioxidants therapy
Kühnau The flavonoids. A class of semi-essential food components: their role in human nutrition
Wollgast et al. Polyphenols in chocolate: is there a contribution to human health?
Lotito et al. Consumption of flavonoid-rich foods and increased plasma antioxidant capacity in humans: cause, consequence, or epiphenomenon?
Manach et al. Polyphenols: food sources and bioavailability
US5650433A (en) Chondroprotective agents
Hu et al. Antioxidant, prooxidant, and cytotoxic activities of solvent-fractionated dandelion (Taraxacum officinale) flower extracts in vitro
Scholz Interactions affecting the bioavailability of dietary polyphenols in vivo
Wiczkowski et al. Quercetin from shallots (Allium cepa L. var. aggregatum) is more bioavailable than its glucosides
Czinner et al. In vitro antioxidant properties of Helichrysum arenarium (L.) Moench
US5650432A (en) Method of treating or preventing non-viral microbial infection
Masibo et al. Major mango polyphenols and their potential significance to human health
Wang The therapeutic potential of flavonoids
Yao et al. Flavonoids in food and their health benefits
Talavera et al. Anthocyanins are efficiently absorbed from the small intestine in rats
Wu et al. Absorption and metabolism of anthocyanins in elderly women after consumption of elderberry or blueberry
Manach et al. Quercetin metabolites in plasma of rats fed diets containing rutin or quercetin
Giampieri et al. The strawberry: composition, nutritional quality, and impact on human health
Thiagarajan et al. Prevention of precancerous colonic lesions in rats by soy flakes, soy flour, genistein, and calcium.
US20050085454A1 (en) Phenolic antioxidant-chromium complexes for treatment or prevention of type 2 diabetes or glucose intolerance
US20060116334A1 (en) Folate based composition for treatment of the cardiovascular system
US20080103118A1 (en) Composition for improving blood cholesterol levels
US20100021573A1 (en) Compositions and methods for the prevention of cardiovascular disease